Peptides DB
Research-centric peptide and protocol reference hub

ACE-031 (ACVR2B-Fc) record · updated 6h ago

Muscle & body compHealing & recoveryGrade A · human clinicalResearch use only
All 8 studiesJump to the evidenceCompare
What is ACE-031 (ACVR2B-Fc) used for?

ACE-031 is an investigational ACVR2B-Fc fusion protein that acts as a myostatin decoy receptor, studied for muscle-wasting conditions like Duchenne muscular dystrophy.

Primarily researched for · Muscle & body comp

Development stage

where ACE-031 (ACVR2B-Fc) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 101 registered trials. It describes the research record, not a recommendation.

Identity
NameACE-031 (ACVR2B-Fc)
Chain length—
Molecular weight—
Formula—
Structure type—
ClassMuscle
Research levelPreclinical
Discovered byCurated master list · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 15, 2026. How this works →
Research stats
Total studies8
Human / animal / cellular2 / 4 / 0
Highest trial phasePreclinical
Years covered2025–2026
Latest study1mo ago
Publication history
20252026
Research funding
42 NIH projects · $37.3M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

8 rowsOpen in the library →
StudyTypeYearSummary depth
Myostatin's flex on the reproductive hormone axis.
TakeawayNot reported in abstract.
—2025Title only0.10
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.
TakeawayNot reported in abstract.
Human2026Title only0.10
Antibodies to watch in 2026.
FindingDevelopment and approval period typically ~6 years.
review2026Full text read0.80
Multi-omics dissection of metabolic hijacking: Infectious bronchitis virus orchestrates lipid-centric replication through PPAR-TGF-β crosstalk.
Finding2.55-fold increase in phosphatidylserine (PS(22:0/22:6))
Animal2026Full text read0.80
Cardiometabolic index (CMI) and sarcopenia as predictors of all-cause and cardiovascular mortality in chronic kidney disease: a NHANES-based cohort study.
FindingHR = 4.03 for cardiovascular mortality in highest CMI quartile, 95% CI: 1.52-10.70
Human2026Full text read0.90
Gel Electrophoretic Detection of Black Market ACE-031.
FindingIn rat serum, BM ACE-031 was detectable up to 48 h post administration.
Animal2025Full text read0.80
ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus).
FindingNot reported in abstract.
Animal2026Partial text0.50
Gel Electrophoretic Detection of Black Market ACE-031.
Finding10 mg/kg body weight administered in rats.
Animal2025Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching ACE-031 (ACVR2B-Fc) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much ACE-031 (ACVR2B-Fc) is discussed should be drawn from it.